Temat: "Bridged Bicyclo Compounds, Heterocyclic" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
Autorzy :: Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Reville P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Issa G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA. .; Pokaż więcej
Źródło :: Blood cancer journal [Blood Cancer J] 2022 May 02; Vol. 12 (5), pp. 77. Date of Electronic Publication: 2022 May 02.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/pharmacology
Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Aged ; Humans ; Prospective Studies ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies ; Sulfonamides ; fms-Like Tyrosine Kinase 3/genetics
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
Autorzy :: Lim B; Research Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea. .
Yoo D; Research Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Chun Y; Pinotbio, Inc, Suwon, Republic of Korea.
Go A; Pinotbio, Inc, Suwon, Republic of Korea.
Cho KJ; Research Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Choi D; Research Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Jung ME; Research Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Lee HY; Pinotbio, Inc, Suwon, Republic of Korea.
Boohaker RJ; Southern Research, Division of Drug Discovery, Birmingham, AL, USA.
Lee JS; Pinotbio, Inc, Suwon, Republic of Korea.
Jung D; Pinotbio, Inc, Suwon, Republic of Korea.
Choi G; Research Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea. .; Pokaż więcej
Źródło :: Blood cancer journal [Blood Cancer J] 2022 Apr 11; Vol. 12 (4), pp. 57. Date of Electronic Publication: 2022 Apr 11.
Typ publikacji :: Letter; Research Support, Non-U.S. Gov't
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/pharmacology
Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use
: Raport

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Autorzy :: Brackman D; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.
Eckert D; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH Co. KG, Ludwigshafen, Germany.
Menon R; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.
Salem AH; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.
Potluri J; Oncology Development, AbbVie Inc., North Chicago, Illinois, USA.
Smith BD; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Wei AH; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Hayslip J; Oncology Development, AbbVie Inc., North Chicago, Illinois, USA.
Miles D; Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.
Mensing S; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH Co. KG, Ludwigshafen, Germany.
Gopalakrishnan S; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH Co. KG, Ludwigshafen, Germany.
Zha J; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.; Pokaż więcej
Źródło :: Hematological oncology [Hematol Oncol] 2022 Apr; Vol. 40 (2), pp. 269-279. Date of Electronic Publication: 2022 Feb 09.
Typ publikacji :: Controlled Clinical Trial; Journal Article
MeSH Terms :: Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Bridged Bicyclo Compounds, Heterocyclic*/adverse effects
Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/etiology
Sulfonamides*/adverse effects
Sulfonamides*/therapeutic use
Humans
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Autorzy :: Ganan-Gomez I; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yang H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ma F; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA.; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thongon N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marchica V; Department of Medicine and Surgery, University of Parma, Parma, Italy.
Richard-Carpentier G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chien K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manyam G; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wang F; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alfonso A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chen S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Class C; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ingram JP; AbbVie Oncology Discovery, Chicago, IL, USA.
Ogoti Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rose A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lockyer P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cambo B; Department of Medicine and Surgery, University of Parma, Parma, Italy.
Muftuoglu M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Schneider S; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adema V; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
McLellan M; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Garza J; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Marchesini M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori', Meldola, Italy.
Giuliani N; Department of Medicine and Surgery, University of Parma, Parma, Italy.
Pellegrini M; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA.
Wang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Walker J; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Li Z; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leverson JD; AbbVie Oncology Discovery, Chicago, IL, USA.
Bueso-Ramos C; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Clise-Dwyer K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Colla S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .; Pokaż więcej
Źródło :: Nature medicine [Nat Med] 2022 Mar; Vol. 28 (3), pp. 557-567. Date of Electronic Publication: 2022 Mar 03.
Typ publikacji :: Journal Article
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/pharmacology
Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/genetics
Myelodysplastic Syndromes*/pathology
Hematopoietic Stem Cells/pathology ; Humans ; Proto-Oncogene Proteins c-bcl-2/genetics ; Sulfonamides
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia.
Autorzy :: Juliusson G; Stem Cell Centre, Department of Laboratory Medicine, Lund University, Lund, S-22100 Lund, Sweden. Electronic address: .; Pokaż więcej
Źródło :: The Lancet. Haematology [Lancet Haematol] 2022 May; Vol. 9 (5), pp. e317-e318.
Typ publikacji :: Journal Article; Comment
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Sulfonamides/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Dezocine relieves the postoperative hyperalgesia in rats through suppressing the hyper-action of Akt1/GSK-3β pathway.
Autorzy :: Gong WY; Department of Anesthesiology, Shanghai General Hospital of Nanjing Medical University, No.100, Haining Road, Hongkou District, Shanghai, 200080, People's Republic of China.; Department of Anesthesiology, Wusong Hospital, No.101, North Tongtai Road, Baoshan District, Shanghai, 200940, People's Republic of China.
Xu B; Department of Anesthesiology, Wusong Hospital, No.101, North Tongtai Road, Baoshan District, Shanghai, 200940, People's Republic of China.
Liu L; Department of Anesthesiology, Wusong Hospital, No.101, North Tongtai Road, Baoshan District, Shanghai, 200940, People's Republic of China.
Li ST; Department of Anesthesiology, Shanghai General Hospital of Nanjing Medical University, No.100, Haining Road, Hongkou District, Shanghai, 200080, People's Republic of China. .; Pokaż więcej
Źródło :: Experimental brain research [Exp Brain Res] 2022 May; Vol. 240 (5), pp. 1435-1444. Date of Electronic Publication: 2022 Mar 25.
Typ publikacji :: Journal Article
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/pharmacology
Hyperalgesia*/drug therapy
Pain, Postoperative*/drug therapy
Pain, Postoperative*/metabolism
Tetrahydronaphthalenes*/pharmacology
Animals ; Glycogen Synthase Kinase 3 beta ; Proto-Oncogene Proteins c-akt ; Rats ; Rats, Sprague-Dawley
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: In situ polymerization of conducting polymers around living neural cells: Cellular effect study.
Autorzy :: Chen HL; School of Animal Science and Technology, Guangxi University, Nanning 530004, Guangxi, People's Republic of China. Electronic address: .
Yang D; School of Animal Science and Technology, Guangxi University, Nanning 530004, Guangxi, People's Republic of China.
Chen CR; School of Animal Science and Technology, Guangxi University, Nanning 530004, Guangxi, People's Republic of China.
Tian GZ; School of Animal Science and Technology, Guangxi University, Nanning 530004, Guangxi, People's Republic of China.
Kim DH; School of Chemical Engineering, Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea; Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea. Electronic address: .; Pokaż więcej
Źródło :: Colloids and surfaces. B, Biointerfaces [Colloids Surf B Biointerfaces] 2022 May; Vol. 213, pp. 112410. Date of Electronic Publication: 2022 Feb 12.
Typ publikacji :: Journal Article
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/pharmacology
Polymers*
Animals ; Electric Conductivity ; Neurons/physiology ; Polymerization ; Rats
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Printed Low-Cost PEDOT:PSS/PVA Polymer Composite for Radiation Sterilization Monitoring.
Autorzy :: Heredia Rivera U; School of Materials Engineering, Purdue University, West Lafayette, Indiana 47907, United States.; Birck Nanotechnology Center, Purdue University, West Lafayette, Indiana 47907, United States.
Kadian S; School of Materials Engineering, Purdue University, West Lafayette, Indiana 47907, United States.; Birck Nanotechnology Center, Purdue University, West Lafayette, Indiana 47907, United States.
Nejati S; School of Materials Engineering, Purdue University, West Lafayette, Indiana 47907, United States.; Birck Nanotechnology Center, Purdue University, West Lafayette, Indiana 47907, United States.
White J; School of Materials Engineering, Purdue University, West Lafayette, Indiana 47907, United States.; Birck Nanotechnology Center, Purdue University, West Lafayette, Indiana 47907, United States.
Sedaghat S; School of Materials Engineering, Purdue University, West Lafayette, Indiana 47907, United States.; Birck Nanotechnology Center, Purdue University, West Lafayette, Indiana 47907, United States.
Mutlu Z; School of Materials Engineering, Purdue University, West Lafayette, Indiana 47907, United States.; Birck Nanotechnology Center, Purdue University, West Lafayette, Indiana 47907, United States.
Rahimi R; School of Materials Engineering, Purdue University, West Lafayette, Indiana 47907, United States.; Birck Nanotechnology Center, Purdue University, West Lafayette, Indiana 47907, United States.; School of Electrical and Computer Engineering, Purdue University, West Lafayette, Indiana 47907, United States.; Pokaż więcej
Źródło :: ACS sensors [ACS Sens] 2022 Apr 22; Vol. 7 (4), pp. 960-971. Date of Electronic Publication: 2022 Mar 25.
Typ publikacji :: Journal Article
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/chemistry
Polymers*/chemistry
Electric Conductivity ; Sterilization
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Support-Free PEDOT:PSS Fibers as Multifunctional Microelectrodes for In Vivo Neural Recording and Modulation.
Autorzy :: Xu T; Department of Chemistry, Renmin University of China, Beijing, 100872, China.
Ji W; Department of Chemistry, Renmin University of China, Beijing, 100872, China.
Wang X; Department of Chemistry, Renmin University of China, Beijing, 100872, China.
Zhang Y; Department of Chemistry, Renmin University of China, Beijing, 100872, China.
Zeng H; Department of Chemistry, Renmin University of China, Beijing, 100872, China.
Mao L; College of Chemistry, Beijing Normal University, Beijing, 100875, China.
Zhang M; Department of Chemistry, Renmin University of China, Beijing, 100872, China.; Pokaż więcej
Źródło :: Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2022 Apr 11; Vol. 61 (16), pp. e202115074. Date of Electronic Publication: 2022 Feb 21.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*
Polymers*
Electric Conductivity ; Microelectrodes
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Understanding PEDOT doped with tosylate.
Autorzy :: Evans DR; Future Industries Institute, University of South Australia, Mawson Lakes, South Australia, 5095, Australia. .; Pokaż więcej
Źródło :: Chemical communications (Cambridge, England) [Chem Commun (Camb)] 2022 Apr 07; Vol. 58 (29), pp. 4553-4560. Date of Electronic Publication: 2022 Apr 07.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/chemistry
Polymers*/chemistry
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia.
Autorzy :: He L; Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Arnold C; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Thoma J; Physical Chemistry of Biosystems, Institute of Physical Chemistry, Heidelberg University, Heidelberg, Germany.
Rohde C; Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Kholmatov M; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Garg S; Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Hsiao CC; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Viol L; Centre for Organismal Studies (COS)/Centre for Cell and Molecular Biology (ZMBH), University of Heidelberg, Heidelberg, Germany.; German Cancer Research Centre (DKFZ), DKFZ-ZMBH Alliance, Heidelberg, Germany.
Zhang K; Division of Molecular Embryology, DKFZ-ZMBH Alliance, Heidelberg, Germany.
Sun R; Division of Molecular Embryology, DKFZ-ZMBH Alliance, Heidelberg, Germany.
Schmidt C; Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Janssen M; Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
MacRae T; Laboratory of Molecular Genetics of Stem Cells, Institute for Research in Immunology and Cancer, University of Montreal, Montreal, Quebec, Canada.
Huber K; Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Thiede C; Department of Internal Medicine I, University Hospital of Dresden Carl Gustav Carus, Dresden, Germany.
Hébert J; The Quebec Leukemia Cell Bank and Division of Hematology-Oncology, Maisonneuve-Rosemont Hospital, Montréal, Canada.; Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, Canada.; Division of Hematology-Oncology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
Sauvageau G; Laboratory of Molecular Genetics of Stem Cells, Institute for Research in Immunology and Cancer, University of Montreal, Montreal, Quebec, Canada.; Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, Canada.; Division of Hematology-Oncology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
Spratte J; Department of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany.
Fluhr H; Department of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany.
Aust G; Department of Surgery, Research Laboratories, Leipzig University, Leipzig, Germany.
Müller-Tidow C; Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Niehrs C; Division of Molecular Embryology, DKFZ-ZMBH Alliance, Heidelberg, Germany.; Institute of Molecular Biology (IMB), Mainz, Germany.
Pereira G; Centre for Organismal Studies (COS)/Centre for Cell and Molecular Biology (ZMBH), University of Heidelberg, Heidelberg, Germany.; German Cancer Research Centre (DKFZ), DKFZ-ZMBH Alliance, Heidelberg, Germany.
Hamann J; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Tanaka M; Physical Chemistry of Biosystems, Institute of Physical Chemistry, Heidelberg University, Heidelberg, Germany.; Center for Integrative Medicine and Physics, Institute for Advanced Study, Kyoto University, Kyoto, Japan.
Zaugg JB; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Pabst C; Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Pokaż więcej
Źródło :: EMBO molecular medicine [EMBO Mol Med] 2022 Apr 07; Vol. 14 (4), pp. e14990. Date of Electronic Publication: 2022 Mar 07.
Typ publikacji :: Journal Article
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/pharmacology
Cyclin-Dependent Kinases*/antagonists & inhibitors
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/metabolism
Leukemia, Myeloid, Acute*/pathology
Protein Kinase Inhibitors*/pharmacology
Sulfonamides*/pharmacology
Antineoplastic Combined Chemotherapy Protocols/pharmacology ; CDC2 Protein Kinase/antagonists & inhibitors ; Drug Synergism ; Hedgehog Proteins/metabolism ; Hedgehog Proteins/therapeutic use ; Humans ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/pathology ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Proto-Oncogene Proteins c-bcl-2/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: High-Throughput PEDOT:PSS/PtNPs-Modified Microelectrode Array for Simultaneous Recording and Stimulation of Hippocampal Neuronal Networks in Gradual Learning Process.
Autorzy :: Xu S; State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing 100190, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Deng Y; State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China.
Luo J; State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing 100190, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
He E; State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing 100190, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Liu Y; State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing 100190, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Zhang K; State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing 100190, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Yang Y; State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing 100190, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Xu S; State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing 100190, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Sha L; State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China.; Neuroscience Center, Chinese Academy of Medical Sciences, Beijing 100005, China.
Song Y; State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing 100190, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Xu Q; State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China.; Neuroscience Center, Chinese Academy of Medical Sciences, Beijing 100005, China.
Cai X; State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing 100190, China.; University of Chinese Academy of Sciences, Beijing 100049, China.; Pokaż więcej
Źródło :: ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2022 Apr 06; Vol. 14 (13), pp. 15736-15746. Date of Electronic Publication: 2022 Mar 16.
Typ publikacji :: Journal Article
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*
Neurons*/physiology
Hippocampus/physiology ; Microelectrodes ; Polymers
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Poly(3,4-ethylenedioxythiophene)-Based Neural Interfaces for Recording and Stimulation: Fundamental Aspects and In Vivo Applications.
Autorzy :: Bianchi M; Center for Translational Neurophysiology of Speech and Communication, Fondazione Istituto Italiano di Tecnologia, via Fossato di Mortara 17, Ferrara, 44121, Italy.
De Salvo A; Center for Translational Neurophysiology of Speech and Communication, Fondazione Istituto Italiano di Tecnologia, via Fossato di Mortara 17, Ferrara, 44121, Italy.; Sezione di Fisiologia, Università di Ferrara, via Fossato di Mortara 17, Ferrara, 44121, Italy.
Asplund M; Division of Nursing and Medical Technology, Luleå University of Technology, Luleå, 971 87, Sweden.; Department of Microsystems Engineering-IMTEK, University of Freiburg, Freiburg, 79110, Germany.; BrainLinks-BrainTools Center, University of Freiburg, Freiburg, 79110, Germany.
Carli S; Center for Translational Neurophysiology of Speech and Communication, Fondazione Istituto Italiano di Tecnologia, via Fossato di Mortara 17, Ferrara, 44121, Italy.
Di Lauro M; Center for Translational Neurophysiology of Speech and Communication, Fondazione Istituto Italiano di Tecnologia, via Fossato di Mortara 17, Ferrara, 44121, Italy.
Schulze-Bonhage A; BrainLinks-BrainTools Center, University of Freiburg, Freiburg, 79110, Germany.; Epilepsy Center, Faculty of Medicine, University of Freiburg, Freiburg, 79110, Germany.
Stieglitz T; Department of Microsystems Engineering-IMTEK, University of Freiburg, Freiburg, 79110, Germany.; BrainLinks-BrainTools Center, University of Freiburg, Freiburg, 79110, Germany.
Fadiga L; Center for Translational Neurophysiology of Speech and Communication, Fondazione Istituto Italiano di Tecnologia, via Fossato di Mortara 17, Ferrara, 44121, Italy.; Sezione di Fisiologia, Università di Ferrara, via Fossato di Mortara 17, Ferrara, 44121, Italy.
Biscarini F; Center for Translational Neurophysiology of Speech and Communication, Fondazione Istituto Italiano di Tecnologia, via Fossato di Mortara 17, Ferrara, 44121, Italy.; Life Science Department, Università di Modena e Reggio Emilia, Via Campi 103, Modena, 41125, Italy.; Pokaż więcej
Źródło :: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2022 Apr; Vol. 9 (12), pp. e2104701. Date of Electronic Publication: 2022 Feb 21.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*
Polymers*/chemistry
Electric Conductivity ; Electrodes
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Electrosynthesis of Biocompatible Free-Standing PEDOT Thin Films at a Polarized Liquid|Liquid Interface.
Autorzy :: Lehane RA; Bernal Institute, University of Limerick (UL), Limerick V94 T9PX, Ireland.; Department of Chemical Sciences, School of Natural Sciences, University of Limerick (UL), Limerick V94 T9PX, Ireland.
Gamero-Quijano A; Bernal Institute, University of Limerick (UL), Limerick V94 T9PX, Ireland.; Department of Chemical Sciences, School of Natural Sciences, University of Limerick (UL), Limerick V94 T9PX, Ireland.
Malijauskaite S; Bernal Institute, University of Limerick (UL), Limerick V94 T9PX, Ireland.; Department of Chemical Sciences, School of Natural Sciences, University of Limerick (UL), Limerick V94 T9PX, Ireland.
Holzinger A; Bernal Institute, University of Limerick (UL), Limerick V94 T9PX, Ireland.; Department of Chemical Sciences, School of Natural Sciences, University of Limerick (UL), Limerick V94 T9PX, Ireland.
Conroy M; Bernal Institute, University of Limerick (UL), Limerick V94 T9PX, Ireland.; Department of Physics, School of Natural Sciences, University of Limerick (UL), Limerick V94 T9PX, Ireland.
Laffir F; Bernal Institute, University of Limerick (UL), Limerick V94 T9PX, Ireland.
Kumar A; School of Mathematics and Physics, Queen's University Belfast (QUB), Belfast BT71 NN, UK.
Bangert U; Bernal Institute, University of Limerick (UL), Limerick V94 T9PX, Ireland.; Department of Physics, School of Natural Sciences, University of Limerick (UL), Limerick V94 T9PX, Ireland.
McGourty K; Bernal Institute, University of Limerick (UL), Limerick V94 T9PX, Ireland.; Department of Chemical Sciences, School of Natural Sciences, University of Limerick (UL), Limerick V94 T9PX, Ireland.; Health Research Institute (HRI), University of Limerick (UL), Limerick V94 T9PX, Ireland.
Scanlon MD; Bernal Institute, University of Limerick (UL), Limerick V94 T9PX, Ireland.; Department of Chemical Sciences, School of Natural Sciences, University of Limerick (UL), Limerick V94 T9PX, Ireland.; The Advanced Materials and Bioengineering Research (AMBER) Centre, CRANN Institute, Trinity College Dublin (TCD), Dublin 2 D02 PN40, Ireland.; Pokaż więcej
Źródło :: Journal of the American Chemical Society [J Am Chem Soc] 2022 Mar 23; Vol. 144 (11), pp. 4853-4862. Date of Electronic Publication: 2022 Mar 09.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/chemistry
Polymers*/chemistry
Electric Conductivity ; Electrodes
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Photoelectrocatalytic mechanism of PEDOT modified filtration membrane.
Autorzy :: Shi L; Key Laboratory of Northwest Water Resource, Environment and Ecology, MOE, Xi'an University of Architecture and Technology, Xi'an 710055, China; Key Laboratory of Membrane Separation of Shaanxi Province, Xi'an University of Architecture and Technology, Xi'an 710055, China.
Liu J; Key Laboratory of Northwest Water Resource, Environment and Ecology, MOE, Xi'an University of Architecture and Technology, Xi'an 710055, China; Key Laboratory of Membrane Separation of Shaanxi Province, Xi'an University of Architecture and Technology, Xi'an 710055, China. Electronic address: .
Gao B; Key Laboratory of Northwest Water Resource, Environment and Ecology, MOE, Xi'an University of Architecture and Technology, Xi'an 710055, China; Key Laboratory of Membrane Separation of Shaanxi Province, Xi'an University of Architecture and Technology, Xi'an 710055, China.
Sillanpää M; Department of Chemical Engineering, School of Mining, Metallurgy and Chemical Engineering, University of Johannesburg, P. O. Box 17011, Doornfontein 2028, South Africa; Chemistry Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia; Aculty of Science and Technology, School of Applied Physics, University Kebangsaan Malaysia, 43600 Bangi, Selangor, Malaysia; International Research Centre of Nanotechnology for Himalayan Sustainability (IRCNHS), Shoolini University, Solan 173212, Himachal Pradesh, India.; Pokaż więcej
Źródło :: The Science of the total environment [Sci Total Environ] 2022 Mar 20; Vol. 813, pp. 152397. Date of Electronic Publication: 2021 Dec 16.
Typ publikacji :: Journal Article
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*
Polymers*
Free Radicals ; Oxidation-Reduction
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: [Efficacy analysis of Venetoclax combined with TKI and dexamethasone-containing low-dose chemotherapy for relapsed/refractory Ph acute B-lymphoblastic leukemia].
Autorzy :: Tian Y; Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Ai H; Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Ji X; Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Wei XD; Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Song YP; Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Yin QS; Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.; Pokaż więcej
Źródło :: Zhonghua yi xue za zhi [Zhonghua Yi Xue Za Zhi] 2022 Mar 15; Vol. 102 (10), pp. 745-748.
Typ publikacji :: Journal Article
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Dexamethasone/therapeutic use ; Humans ; Protein Kinase Inhibitors/therapeutic use ; Sulfonamides
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Tailoring conductive inverse opal films with anisotropic elliptical porous patterns for nerve cell orientation.
Autorzy :: Zhang Z; Department of Clinical Laboratory, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, China.; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China.
Wang Y; Department of Clinical Laboratory, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, China.
Chen Z; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China.
Xu D; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China.
Zhang D; Department of Clinical Laboratory, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, China. .; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China. .
Wang F; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China. .; Department of Dermatology, Zhongda Hospital, Southeast University, Nanjing, 210009, China. .
Zhao Y; Department of Clinical Laboratory, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, China. .; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China. .; Pokaż więcej
Źródło :: Journal of nanobiotechnology [J Nanobiotechnology] 2022 Mar 09; Vol. 20 (1), pp. 117. Date of Electronic Publication: 2022 Mar 09.
Typ publikacji :: Journal Article
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/chemistry
Polymers*/chemistry
Electric Conductivity ; Neurons ; Porosity
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 18 18.

Tytuł :: Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Autorzy :: Cathelin S; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Sharon D; Oncology Discovery, AbbVie Inc., North Chicago, IL, USA.
Subedi A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Cojocari D; Oncology Discovery, AbbVie Inc., North Chicago, IL, USA.
Phillips DC; Oncology Discovery, AbbVie Inc., North Chicago, IL, USA.
Leverson JD; Oncology Development, AbbVie Inc., North Chicago, IL, USA.
MacBeth KJ; Bristol Myers Squibb, Summit, NJ, USA.
Nicolay B; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Narayanaswamy R; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Ronseaux S; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Liu G; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Chan SM; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .; Pokaż więcej
Źródło :: Leukemia [Leukemia] 2022 Mar; Vol. 36 (3), pp. 869-872. Date of Electronic Publication: 2021 Nov 06.
Typ publikacji :: Letter
MeSH Terms :: Aminopyridines/*pharmacology
Antineoplastic Agents/*pharmacology
Bridged Bicyclo Compounds, Heterocyclic/*pharmacology
Enzyme Inhibitors/*pharmacology
Isocitrate Dehydrogenase/*genetics
Leukemia, Myeloid, Acute/*drug therapy
Sulfonamides/*pharmacology
Triazines/*pharmacology
Aminopyridines/therapeutic use ; Animals ; Antineoplastic Agents/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Cell Line, Tumor ; Enzyme Inhibitors/therapeutic use ; Humans ; Isocitrate Dehydrogenase/antagonists & inhibitors ; Leukemia, Myeloid, Acute/genetics ; Mutation/drug effects ; Sulfonamides/therapeutic use ; Triazines/therapeutic use
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Autorzy :: Salhotra A; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Tsai NC; Department of Information Sciences, City of Hope National Medical Center, Duarte, CA, USA.
Zhang J; Department of Information Sciences, City of Hope National Medical Center, Duarte, CA, USA.
Ngo D; Department of Clinical Pharmacology, City of Hope National Medical Center, Duarte, CA, USA.
Aribi A; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Sandhu K; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Ball B; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Al-Malki M; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Ali H; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Koller P; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Artz A; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Forman S; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Nakamura R; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Stein A; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Marcucci G; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Aldoss I; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.
Pullarkat V; Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA, USA.; Pokaż więcej
Źródło :: British journal of haematology [Br J Haematol] 2022 Mar; Vol. 196 (6), pp. e71-e74. Date of Electronic Publication: 2021 Dec 21.
Typ publikacji :: Letter
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use
Leukemia, Myeloid, Acute*/chemically induced
Leukemia, Myeloid, Acute*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Sulfonamides/therapeutic use
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Autorzy :: Blombery P; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; University of Melbourne, Melbourne, VIC, Australia.; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Lew TE; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Dengler MA; University of Melbourne, Melbourne, VIC, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; Division on Oncology, Medical University of Graz, Graz, Austria; and.
Thompson ER; University of Melbourne, Melbourne, VIC, Australia.; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Lin VS; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; University of Melbourne, Melbourne, VIC, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Chen X; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Nguyen T; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Panigrahi A; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Handunnetti SM; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Carney DA; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; University of Melbourne, Melbourne, VIC, Australia.
Westerman DA; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; University of Melbourne, Melbourne, VIC, Australia.; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Tam CS; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; University of Melbourne, Melbourne, VIC, Australia.
Adams JM; University of Melbourne, Melbourne, VIC, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Wei AH; The Alfred Hospital and Monash University, Melbourne, VIC, Australia.
Huang DCS; University of Melbourne, Melbourne, VIC, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Seymour JF; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; University of Melbourne, Melbourne, VIC, Australia.
Roberts AW; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; University of Melbourne, Melbourne, VIC, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Anderson MA; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; Pokaż więcej
Źródło :: Blood [Blood] 2022 Feb 24; Vol. 139 (8), pp. 1198-1207.
Typ publikacji :: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :: Bridged Bicyclo Compounds, Heterocyclic*/administration & dosage
Bridged Bicyclo Compounds, Heterocyclic*/adverse effects
Hematologic Neoplasms*/genetics
Hematologic Neoplasms*/metabolism
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Leukemia, Lymphocytic, Chronic, B-Cell*/metabolism
Mutation*
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/metabolism
Neoplasms, Second Primary*/genetics
Neoplasms, Second Primary*/metabolism
Sulfonamides*/administration & dosage
Sulfonamides*/adverse effects
bcl-2-Associated X Protein*/antagonists & inhibitors
bcl-2-Associated X Protein*/genetics
bcl-2-Associated X Protein*/metabolism
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Myelopoiesis/*drug effects
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Vidarabine/analogs & derivatives
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Bridged Bicyclo Compounds, Heterocyclic"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język